Virmani K, Widhalm K
Dept. of Pediatrics, University of Vienna, Austria.
J Am Coll Nutr. 1993 Apr;12(2):115-24. doi: 10.1080/07315724.1993.10718291.
Histidemia, first described by Ghadimi in 1961, is caused by a defect in histidase. The defect results in elevated urinary excretion of histidine and its transamination products, and in high blood histidine. Blood histidine levels in histidinemic patients range from 290 to 1420 microM (normal 70-120 microM). The clinical picture of histidinemia varies from complete normality to severe retardation, with many patients being asymptomatic. No correlation has been found between clinical and biochemical data. Most reported cases have been identified in newborn screening programs. Frequency of histidinemia ranges from 1 in 8000 (Japan) to 1 in 37,000 (Sweden). Histidinemia is inherited as an autosomal recessive trait. Maternal histidinemia is believed to be benign. Studies in animal models have shown similar metabolic changes in animals and humans, but clinical changes differ. Histidinemia may be treated with a low-histidine diet, which reduces elevated histidine levels, although in most cases no improvement of clinical symptoms has been observed.
组氨酸血症由加迪米于1961年首次描述,是由组氨酸酶缺陷引起的。该缺陷导致尿中组氨酸及其转氨产物排泄增加,以及血中组氨酸水平升高。组氨酸血症患者的血组氨酸水平在290至1420微摩尔/升之间(正常为70 - 120微摩尔/升)。组氨酸血症的临床表现从完全正常到严重智力迟钝不等,许多患者无症状。临床和生化数据之间未发现相关性。大多数报告的病例是在新生儿筛查项目中发现的。组氨酸血症的发病率从八千分之一(日本)到三万七千分之一(瑞典)不等。组氨酸血症作为常染色体隐性性状遗传。母体组氨酸血症被认为是良性的。动物模型研究表明,动物和人类有相似的代谢变化,但临床变化不同。组氨酸血症可用低组氨酸饮食治疗,这可降低升高的组氨酸水平,不过在大多数情况下,未观察到临床症状改善。